One of such approaches is represented by a combination of abiraterone, a novel hormone therapy available for CRPC (85), and tildrakizumab (anti-IL-23 mAb) (NCT04458311), altering the production of IL-23 and therefore having a potential to target the MDSCs function specific for PC (41). The gene discussed is IL23A; the disease is pachyonychia congenita.